All In Biotech

Drug Trial Radar · NCT02401971

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial

Last checked: Nov 19, 2026Latest source record: Mar 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

900

Planned (sponsor's estimate)

Start

Aug 2014

Primary completion

Aug 2016

Study completion Aug 2018

Sponsor

Lead sponsor
Wang JufengAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The First Affiliated Hospital of Zhengzhou University; Henan Provincial People's Hospital; Second Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Henan University of Science and Technology
First posted
Mar 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recent clinical studies have demonstrated a reduction of irinotecan (CPT-11) gastrointestinal toxicities when the CPT-11 is administered in combination with thalidomide in patients with diagnosis of gastric cancer. The main purpose of this study is to investigate the efficacy and safety of thalidomide and CPT-11 in advanced gastric cancer. The investigators will also manage to find out the possible interactions between CPT-11 pharmacokinetics and thalidomide to explain the previously described gastrointestinal toxicity reduction.

Conditions

  • Gastric Cancer

Interventions

  • ThalidomideDrug

    Given orally

  • CPT-11Drug

    Given Ivgtt

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time to progression(TTP)Time frame: up to 2 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.